GlaxoSmithKline gets order for 60m swine flu vaccines from the UK

The company, which already manufactures one of the key anti-viral treatments for the virus, Relenza, has also received millions of orders from other European governments including France.

GSK, led by chief executive Andrew Witty, said it expects to manufacture a vaccine for the H1N1 strain as soon as a virus seed is made available by the World Health Organisation (WHO). The first doses are expected to be available four to six months later, subject to regulatory approval.

FULL ARTICLE HERE